Eosinophilic Granulomatosis With Polyangiitis Following COVID-19 Vaccination: A Case Report

J Korean Med Sci. 2023 Dec 11;38(48):e382. doi: 10.3346/jkms.2023.38.e382.

Abstract

The current emergence of the coronavirus disease 2019 (COVID-19) pandemic and the possible side effects of COVID-19 mRNA vaccination remain worrisome. Few cases of vaccination-related side effects, such as vasculitis, have been reported. Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome, is a type of vasculitis characterized by the histological richness of eosinophils, asthma, polyneuropathy, sinusitis, and skin or lung involvement. Here, we report the first case of new onset EGPA following COVID-19 vaccination in Korea. A 71-year old woman developed a skin rash and presented with progressive weakness of the upper and lower extremities after the BNT162b2 vaccination (Pfizer-BioNTech). She was diagnosed with EGPA and her symptoms improved after systemic steroid and immunosuppressant therapy. Although it is very rare, clinicians should be aware that EGPA may occur after COVID-19 vaccination.

Keywords: COVID-19; Churg-Strauss Syndrome; Vaccination.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • BNT162 Vaccine
  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / prevention & control
  • Churg-Strauss Syndrome* / diagnosis
  • Churg-Strauss Syndrome* / drug therapy
  • Churg-Strauss Syndrome* / etiology
  • Female
  • Granulomatosis with Polyangiitis* / diagnosis
  • Granulomatosis with Polyangiitis* / therapy
  • Humans

Substances

  • BNT162 Vaccine
  • COVID-19 Vaccines